Miranda Isom
Nurse Practitioner · Phoenix, AZNPI 1497023865
Payments from drug & device makers
Across 917 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- AbbVie$4K
- UCB, Inc.$2K
- Pfizer$1K
- Lilly USA, LLC$1K
- AstraZeneca$803
- plus $4K from 22 others
What the payments were for
- Food & beverage$17,211100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 243 | $4,490 |
| AbbVie | 239 | $3,929 |
| UCB, Inc. | 70 | $1,796 |
| Pfizer | 75 | $1,180 |
| Lilly USA, LLC | 49 | $1,035 |
| AstraZeneca(2 entities) | 47 | $803 |
| Novartis | 38 | $734 |
| Johnson & Johnson(3 entities) | 28 | $525 |
| GSK | 22 | $376 |
| Mallinckrodt Hospital Products Inc. | 11 | $282 |
| E.r. Squibb & Sons, L.L.C. | 12 | $244 |
| Sanofi | 9 | $228 |
| Organon | 13 | $210 |
| Radius Health, Inc. | 10 | $200 |
| Aurinia Pharma U.S., Inc. | 9 | $198 |
| Actelion Pharmaceuticals US, Inc. | 7 | $197 |
| Boehringer Ingelheim | 8 | $186 |
| Genentech USA, Inc. | 7 | $169 |
| Fresenius Kabi USA, LLC | 5 | $134 |
| Ferring Pharmaceuticals Inc. | 6 | $100 |
| Tersera Therapeutics LLC | 1 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Fidia Pharma USA Inc. | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Pacira Therapeutics, Inc. | 1 | $21 |
| Sandoz | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
How this compares
$17,211 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 19 | $271,452 |
| Enbrel SureclickEtanercept | 18 | $142,407 |
| Enbrel MiniEtanercept | 13 | $95,713 |
| Hydroxychloroquine Sulfate | 230 | $9,692 |
| MethotrexateMethotrexate Sodium | 365 | $9,189 |
| SavellaMilnacipran Hcl | 11 | $8,856 |
| Leflunomide | 118 | $6,358 |
| Prednisone | 313 | $2,639 |
| Ibandronate Sodium | 69 | $2,375 |
| Duloxetine Hcl | 41 | $1,157 |
| Sulfasalazine DrSulfasalazine | 16 | $1,113 |
| Folic Acid | 68 | $984 |
| Colchicine | 13 | $766 |
| Febuxostat | 16 | $744 |
| Gabapentin | 39 | $726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSavella | $3,929 | $8,85611 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $15 | $76613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,719 nurse practitioner providers in Arizona.
Other nurse practitioner in Phoenix
- Helena In't VeldPhoenix$64K
- Dustin NickersonPhoenix$39K
- Ryan MobleyPhoenix$22K
- Anita PalandriPhoenix$20K
- Kristina WernerPhoenix$19K
- Catherine LynnPhoenix$16K
- Edith GazoPhoenix$15K
- Dora QuanPhoenix$14K
- Rachael BennettPhoenix$14K
- Marianne RosatiPhoenix$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.